Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma.

IF 1.5 4区医学 Q3 DERMATOLOGY

Melanoma Research Pub Date : 2024-04-01 Epub Date: 2023-12-01 DOI:10.1097/CMR.0000000000000947

Ganesh Vigneswaran, Weeratunge Malalasekera, Victoria Smith, Tom Gibson, Shian Patel, Matthew Wheater, Ioannis Karydis, Sanjay Gupta, Brian Stedman, Sachin Modi

{"title":"Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma.","authors":"Ganesh Vigneswaran, Weeratunge Malalasekera, Victoria Smith, Tom Gibson, Shian Patel, Matthew Wheater, Ioannis Karydis, Sanjay Gupta, Brian Stedman, Sachin Modi","doi":"10.1097/CMR.0000000000000947","DOIUrl":null,"url":null,"abstract":"Background: Recent studies indicate that melphalan percutaneous hepatic perfusion (M-PHP) for liver metastases from ocular melanoma (mUM) improves survival. Importantly, this benefit must be carefully balanced with changes in a patient's quality of life (QoL). This study examines the QoL changes post-M-PHP.Methods: Retrospective analysis of the change in QoL using the Functional Assessment of Cancer Therapy-General (FACT-G) with mUM patients receiving M-PHP ( n = 20). The FACT-G scores, which comprise physical (PWB), social (SWB), emotional (EWB) and functional (FWB) wellbeing were measured pre-procedure and at day 1, day of discharge (mean = 2.4 days), 7, 14 and 28 days after M-PHP therapy. Wilcoxon signed-rank test gauged QoL domain changes.Results: Baseline FACT-G median (IQR) scores were 101.8 (21.8). QoL scoring significantly decreased immediately after the procedure [day 1; 85 (27.5); P = 0.002] and gradually improved over time. By day 28, QoL almost returned to pre-procedure levels [100.3 (13.8); P = 0.31]. Subscore analysis revealed that the initial drop in QoL at day 1 post-procedure was attributable to the PWB (28 vs. 24; P = 0.001) and FWB domains (26 vs. 18.5; P < 0.001). By day 28 there was a statistically significant improvement in EWB ( P = 0.01).Conclusion: QoL following M-PHP decreases immediately after therapy and is not significantly different from baseline by the day of discharge. By day 28 there is improved emotional well-being. This study could help to optimize the time between treatment cycles when combined with toxicity data and blood count recovery.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906212/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CMR.0000000000000947","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recent studies indicate that melphalan percutaneous hepatic perfusion (M-PHP) for liver metastases from ocular melanoma (mUM) improves survival. Importantly, this benefit must be carefully balanced with changes in a patient's quality of life (QoL). This study examines the QoL changes post-M-PHP.

Methods: Retrospective analysis of the change in QoL using the Functional Assessment of Cancer Therapy-General (FACT-G) with mUM patients receiving M-PHP ( n = 20). The FACT-G scores, which comprise physical (PWB), social (SWB), emotional (EWB) and functional (FWB) wellbeing were measured pre-procedure and at day 1, day of discharge (mean = 2.4 days), 7, 14 and 28 days after M-PHP therapy. Wilcoxon signed-rank test gauged QoL domain changes.

Results: Baseline FACT-G median (IQR) scores were 101.8 (21.8). QoL scoring significantly decreased immediately after the procedure [day 1; 85 (27.5); P = 0.002] and gradually improved over time. By day 28, QoL almost returned to pre-procedure levels [100.3 (13.8); P = 0.31]. Subscore analysis revealed that the initial drop in QoL at day 1 post-procedure was attributable to the PWB (28 vs. 24; P = 0.001) and FWB domains (26 vs. 18.5; P < 0.001). By day 28 there was a statistically significant improvement in EWB ( P = 0.01).

Conclusion: QoL following M-PHP decreases immediately after therapy and is not significantly different from baseline by the day of discharge. By day 28 there is improved emotional well-being. This study could help to optimize the time between treatment cycles when combined with toxicity data and blood count recovery.

查看原文本刊更多论文

转移性葡萄膜黑色素瘤患者美法仑经皮肝灌注术后的生活质量。

背景：最近的研究表明，美法仑经皮肝灌注（M-PHP）治疗眼黑色素瘤（mUM）肝转移可提高生存率。重要的是，这种益处必须与患者生活质量（QoL）的变化谨慎平衡。本研究探讨了M-PHP术后生活质量的变化：方法：使用癌症治疗功能评估（FACT-G）对接受M-PHP治疗的MUM患者（20人）的生活质量变化进行回顾性分析。FACT-G评分包括身体（PWB）、社交（SWB）、情感（EWB）和功能（FWB）健康状况，在治疗前、第1天、出院当天（平均=2.4天）、M-PHP治疗后7天、14天和28天进行测量。Wilcoxon 符号秩检验衡量 QoL 领域的变化：结果：基线 FACT-G 中位数（IQR）为 101.8（21.8）分。手术后[第 1 天；85 (27.5); P = 0.002]，QoL 评分立即明显下降，并随着时间的推移逐渐提高。到第 28 天，QoL 几乎恢复到手术前的水平 [100.3 (13.8); P = 0.31]。分值分析表明，术后第 1 天 QoL 最初的下降主要归因于 PWB（28 vs. 24；P = 0.001）和 FWB 领域（26 vs. 18.5；P 结论：M-PHP 术后 QoL 下降的主要原因是术后第 1 天 QoL 的下降：M-PHP 治疗后的 QoL 立即下降，到出院当天与基线无明显差异。到第 28 天，患者的情绪健康状况有所改善。这项研究结合毒性数据和血细胞计数恢复情况，有助于优化治疗周期之间的间隔时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Research 医学-皮肤病学

CiteScore

3.40

自引率

4.50%

发文量

139

审稿时长

6-12 weeks

期刊介绍： Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.